210 likes | 461 Vues
HIP RESURFACING. Conserve Plus FDA Post Approval Study Began September 2010 10 year study group 132 of 353 Cases 10mm design 896 at Salem Hospital. Harold S. Boyd, MD. 12/2011. 10 year FDA Study. MOM . Different designs— THRs and SRs. Zimmer THR 510K.
E N D
HIP RESURFACING • Conserve Plus FDA Post Approval Study • Began September 2010 • 10 year study group 132 of 353 Cases • 10mm design • 896 at Salem Hospital Harold S. Boyd, MD 12/2011
MOM Different designs— THRs and SRs
All Prostheses have ionic wearTKR study 3.4ppb(Parts Per Billion)
Current FDA study 125/133 Conserve+ at 10 years2.2ppbCormet at 5 years2.07ppb(1.7ppb normal)
Stems defeat THRs 40 years
Surface replacement without stress riser Patients outlive their stem
What Does Resurfacing Do? • Normal Biomechanics • Active lifestyle • Easy revision • Reproduces patient’s anatomy
STUDY FINDS SR OFFERS CLINICAL BENEFITS OVER TOTAL HIP • More precise • More active at one year • Pain, length, limp • Less stress shielding noted • 800/1400 U. Wisconsin---blinded Dr Robert L. Barrack Current Concepts 2010 Winter Meeting
New operation forUnusual Diagnoses • Previous femoral fractures • Osteogenesis imperfecta • Gaucher’s disease • Restoring acetabular offset secondary to protrusio and pelvic fractures
Disclosures/Handouts • Wright Medical & Corin
Rather than a “RISK” Resurfacing is a ‘STRENGTH’ for Salem Hospital